Verified July 2026 · Cited to primary sources
Every peptide,
graded by the evidence.
Most research peptides — BPC-157, TB-500, KPV, MOTS-c — are not FDA-approved, and their human evidence is animal-only (Grade D). We grade all 13 by strength of human proof (A–F) and legal status, so you get the honest verdict — not gray-market hype.
- Graded
- 13
- FDA docket
- 6
- FDA-approved
- 1
peptides, A–F
PCAC vote Jul 23–24
of these (tesamorelin)
FDA decision incoming
The FDA votes on 7 peptides — July 23–24, 2026.
the committee decides whether BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon can be legally compounded under the 503A bulks list.
The trust moat
What the evidence grades mean.
One question — how strong is the human proof? — answered by a fixed rule, not by what we can sell. FDA approval and human trials sit at the top; animal-only and failed-in-humans at the bottom. Legal status is graded separately as a factual badge.
- Grade A
- FDA-approved / proven in humans
- Grade B
- Real human trials, limited or historical
- Grade C
- Early / foreign human data only
- Grade D
- Animal studies only, unproven in humans
- Grade F
- Tested in humans and failed
The Evidence Grades
All 13 peptides, graded A–F.
Ranked by strength of human evidence — never by what we can monetize. How we grade.
| Peptide | Evidence | |
|---|---|---|
| Tesamorelin Synthetic GHRH | Grade A FDA-approved / proven in humans | See the evidence → |
| PT-141 Synthetic melanocortin receptor agonist | Grade A FDA-approved / proven in humans | See the evidence → |
| Sermorelin Synthetic GHRH | Grade B Real human trials, limited or historical | See the evidence → |
| Retatrutide Investigational GIP/GLP-1/glucagon triple-receptor agonist peptide | Grade B Real human trials, limited or historical | See the evidence → |
| GHK-Cu Copper-binding tripeptide complex | Grade B Real human trials, limited or historical | See the evidence → |
| Semax Synthetic heptapeptide | Grade C Early / foreign human data only | See the evidence → |
| CJC-1295 / Ipamorelin GHRH analog | Grade C Early / foreign human data only | See the evidence → |
| BPC-157 Synthetic pentadecapeptide | Grade D Animal studies only, unproven in humans | See the evidence → |
| TB-500 Synthetic actin-binding peptide fragment | Grade D Animal studies only, unproven in humans | See the evidence → |
| KPV Synthetic tripeptide | Grade D Animal studies only, unproven in humans | See the evidence → |
| MOTS-c Mitochondrial-derived peptide | Grade D Animal studies only, unproven in humans | See the evidence → |
| Epitalon Synthetic tetrapeptide | Grade D Animal studies only, unproven in humans | See the evidence → |
| IGF-1 LR3 Synthetic long-acting analogue of insulin-like growth factor 1 | Grade D Animal studies only, unproven in humans | See the evidence → |
Methodology: Evidence Grade is assigned by a fixed decision tree (FDA approval and published human RCTs at the top; animal-only and failed-in-humans at the bottom). Affiliate availability never changes a grade. Full methodology.
Best peptide for…
Pick a goal. Get the graded answer.
Weight Loss
Tesamorelin is the only Grade-A option, but it is approved for HIV-associated visceral fat, not general weight loss. Retatrutide (Grade B) is investigational and not legally available. MOTS-c is Grade D. For proven, legally-accessible weight loss today, the evidence points to approved GLP-1 medications — not a research peptide.
See the ranking →
Muscle Growth
Sermorelin (Grade B) is the best-evidenced option with a legal compounding route. Tesamorelin (Grade A) is proven for visceral fat but approved only for HIV lipodystrophy. CJC-1295/Ipamorelin (Grade C) raises GH/IGF-1 in one study but has no trial showing it builds muscle — and it is not legally compoundable.
See the ranking →
Recovery & Healing
The famous recovery peptides — BPC-157, TB-500, KPV — are all Grade D (animal studies only) and under FDA review (July 2026 PCAC). Sermorelin (Grade B) is the only option here with real human data and a legal route. Honest bottom line: the recovery claims outrun the human evidence.
See the ranking →
Skin & Anti-Aging
Among injectable options, KPV and Epitalon are both Grade D — no human efficacy trials. The evidence-backed skin route is topical GHK-Cu (Grade B for topical/cosmetic use), which is legal as a cosmetic and doesn't require injecting anything. We'd point most people there, not to a research injectable.
See the ranking →
Sleep
No peptide here has strong human sleep-efficacy data. Epitalon (Grade D) rests on small Russian studies. Sermorelin (Grade B) is better-evidenced overall and sometimes used for sleep/recovery, but it is a GH-axis peptide, not a dedicated sleep aid. Honest answer: sleep is the weakest-evidence peptide category.
See the ranking →
Hair Growth
The only peptide here with genuine human evidence is topical GHK-Cu (copper peptides), and even that is Grade B for skin with only early, thin hair data — nowhere near the proof behind finasteride and minoxidil, which are not peptides. If regrowing hair is the goal, the evidence points to those proven drugs first; a copper-peptide serum is at best a legal, low-risk supporting cosmetic.
See the ranking →
Start here
Are peptides safe & legal?
The evidence, the July 2026 FDA vote, and why sourcing matters — before you buy anything.
Read the safety guide →
Trying to lose weight?
For weight loss, skip the research peptides.
No peptide on this site has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the GLP-1 options that actually work — honestly, the same way we grade peptides here.
FAQ
Frequently asked questions
What is the best peptide for [goal]?
It depends on the goal — and on being honest about the evidence. For recovery, the famous peptides (BPC-157, TB-500) are Grade D (animal studies only). For muscle, sermorelin (Grade B) is the best-evidenced legal option. For weight loss, no research peptide beats an approved GLP-1 medication. We grade every peptide A–F by human evidence and show its legal status so you can see the honest answer, not the hype.
Are peptides FDA approved?
Most are not. Of the peptides we cover, only tesamorelin (Egrifta, 2010) is FDA-approved, and it is approved for HIV-associated visceral fat — not general use. Sermorelin was formerly approved (Geref) and remains legally compoundable. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon are not approved and are under FDA review (July 2026 PCAC).
Are peptides safe?
It varies, and honest safety data is thin. FDA testing has found that a large share of online/compounded peptides had incorrect dosages or undeclared ingredients — the core reason we grade legal access routes and refuse gray-market vendors. The best-characterized peptides here (tesamorelin, sermorelin) have real human safety data; most others have little to none. Talk to a licensed clinician before starting anything.
What peptides is the FDA reviewing in 2026?
The FDA's Pharmacy Compounding Advisory Committee (PCAC) votes on July 23–24, 2026 on whether seven peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP/Emideltide, Semax and Epitalon — can be legally compounded under the 503A bulks list. Our FDA peptide status tracker covers the outcome.
How do you grade peptides — and are you independent?
Evidence Grade is assigned by a fixed decision tree: FDA approval or multiple human RCTs earn an A, real human trials a B, early or foreign data a C, animal-only a D, and a failed human trial an F. Legal status is a separate, factual badge. Affiliate availability never lifts a grade — an F-grade peptide we can't monetize still gets F. See our editorial policy for the firewall.
The monthly peptide evidence brief.
What the research and the FDA actually say — one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.